MDT

Medtronic is initiated with a buy rating and a $106.33 price target, implying 17% upside and a 3% dividend yield. Q1 FY27 results exceeded expectations, with normalized revenue growth of 7% and notable strength in Cardiovascular and Neuroscience segments. Guidance was raised for revenue and EPS, but margin expansion is expected to materialize gradually as product mix shifts toward higher-margin recurring revenues.

Medtronic delivered solid Q1 FY27 results, with organic revenue growth of ~7%, and raised full-year guidance to 7.25–7.75%. Newer businesses, especially Cardiac Ablation Solutions, are now meaningful contributors, supporting a more robust growth profile for MDT. The MiniMed separation will make MDT smaller but more profitable, with expected margin improvements and a sharper focus on core segments.

Medtronic has trounced the S&P 500 index in recent months. The company's strong showing in Q1 2027 prompted it to raise its non-GAAP EPS guidance for FY 2027. Medtronic's interest coverage ratio and net debt to EBITDA ratio are both healthy.

Boston Scientific faces near-term pressure in electrophysiology, while Medtronic gains share and sees stronger momentum across key franchises.

Trusted vessel-sealing technology used in more than 45 million procedures worldwide is now cleared for robotic-assisted surgery in the U.S. GALWAY, Ireland, Sept. 16, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the LigaSure™ RAS Maryland jaw device for use with the Hugo™ robotic-assisted surgery (RAS) system.

Medtronic NYSE: MDT Chief Financial Officer Thierry Piéton said the medical-device maker's focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are supporting its recent growth momentum.

Medtronic shareholders can exchange their Medtronic  ordinary shares for shares of MiniMed Provides Medtronic shareholders with option for a generally tax-free exchange for  U.S. federal income tax purposes GALWAY, Ireland, Sept. 14, 2026 /PRNewswire/ -- Medtronic plc (Medtronic; NYSE: MDT) today announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED).

NORTHRIDGE, Calif., Sept. 14, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn.

MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

Medtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.